Frontlight ResearchEarly access
TerminatedPhase 1/2
NG2 and DLL3 CAR-T Cells Targeting Melanoma
Key facts
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1/2
- People taking part
- 100 people enrolled
- Started
- 1 Sept 2025
- Ended
- 31 Jul 2026
- Type of study
- Interventional
- Treatments tested
- NG2 and DLL3 CAR-T cells
- Record updated
- 3 November 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (22)Hide the full registry criteria
Who can take part
- Patients with tumors have received standard first-line therapy and have been diagnosed with non-resectable, metastatic, progressive or recurrent conditions
- The expression status of NG2 and DLL3 antigens of the tumor has been determined for eligibility. Positive expression is defined by NG2 and DLL3 antibody staining results based on immunohistochemistry or flow cytometry analyses
- Body weight greater than or equal to 40 kg
- Age: ≥18 year and ≤ 75 years of age at the time of enrollment
- Life expectancy: at least 8 weeks
- Prior Therapy:; There is no limit to the number of prior treatment regimens. Any grade 3 or 4 non-hematologic toxicity of any previous therapy must have resolved to grade 2 or less; Participants must not have received hematopoietic growth factors for at least 1 week prior to mononuclear cells collection; At least 7 days must have elapsed since the completion of therapy with any biologic agent, targeted agent, tyrosine kinase inhibitor or metronomic non-myelosuppressive regimen; At least 4 weeks must have elapsed since prior therapy that includes a monoclonal antibody; At least 1 week must has elapsed since any radiation therapy at the time of study entry
- Karnofsky/jansky score of 70% or greater
- Cardiac function: Left ventricular ejection fraction greater than or equal to 40/55 percent
- Pulse Ox greater than or equal to 90% on room air
- Liver function: defined as alanine transaminase (ALT) <3x upper limit of normal (ULN), aspartate aminotransferase (AST) <3x ULN; serum bilirubin and alkaline phosphatase <2x ULN
- Renal function: Patients must have serum creatinine less than 3 times ULN
- Marrow function: White blood cell count ≥1000/ul, Absolute neutrophil count ≥500/ul, Absolute lymphocyte count ≥500/ul, Platelet count ≥25,000/ul (not achieved by transfusion)
- Patients with known bone marrow metastatic disease will be eligible for study as long as they meet hematologic function criteria, and the marrow disease not evaluable for hematologic toxicity
- For all patients enrolled in this study, their parents or legal guardians must sign an informed consent and assent
Who cannot take part
- Untreated central nervous system (CNS) metastasis; patients with previous CNS tumor involvement that has been treated and is stable for at least 6 weeks following completion of therapy are eligible
- Previous treatment with other genetically engineered CAR T cells
- Patients who require systemic corticosteroid or other immunosuppressive therapy
- Existing severe illness (e.g. significant cardiac, pulmonary, hepatic diseases, etc.) or major organ dysfunction, with the exception of grade 3 hematologic toxicity
- Active HIV, Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection or uncontrolled infection
- Evidence of tumor potentially causing airway obstruction
- Inability to comply with protocol requirements
- Insufficient availability of CART cells
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to assess the feasibility, safety and efficacy of multiple CAR-T cell therapy which targets NG2 and DLL3 surface antigens in patients with relapsed and refractory melanoma.
The group in the trial
- effectiveness of CAR-T cells targeting NG2 and DLL3Treatment being tested
Gene-modified T cells are designed to kill tumor cells through specific recognition of NG2 and DLL3. This study will evaluate the side effects and effective doses of NG2 and DLL3 CAR-T cells in treating refractory and recurrent melanoma
Treatment: NG2 and DLL3 CAR-T cells
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Efficacy of NG2 and DLL3 CAR-T Therapy Targeting Melanoma
- Record updated
- 3 November 2026